222556-21-0 Usage
Description
(S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester is a complex organic compound characterized by a tetrahydropyridazine ring with three carboxylic acid groups. It features two tert-butyl and one methyl ester groups attached to the ring, suggesting potential applications in pharmaceuticals or chemical research due to its unique structure and functional groups.
Uses
Used in Pharmaceutical Industry:
(S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester is used as a potential pharmaceutical agent for its complex structure that may interact with biological targets, offering new avenues for drug development.
Used in Chemical Research:
In the field of chemical research, (S)-tetrahydro-pyridazine-1,2,3-tricarboxylic acid 1,2-di-tert-butyl ester 3-methyl ester serves as a compound of interest for studying its reactivity, stability, and potential to form new derivatives with various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 222556-21-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,2,5,5 and 6 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 222556-21:
(8*2)+(7*2)+(6*2)+(5*5)+(4*5)+(3*6)+(2*2)+(1*1)=110
110 % 10 = 0
So 222556-21-0 is a valid CAS Registry Number.
222556-21-0Relevant articles and documents
MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
-
Paragraph 0390, (2017/08/01)
Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
-
Page/Page column 140; 141, (2014/01/08)
Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
Synthesis of the tripeptide domain of sanglifehrins using asymmetric phase-transfer catalysis
White, James D.,Suttisintong, Khomson
, p. 2757 - 2762 (2013/04/23)
The tripeptide (S)-valinyl-(S)-m-hydroxyphenylalanyl-(3S)-piperazate common to immunosuppressant sanglifehrins was synthesized from the constituent amino acid residues in nine steps and 42% overall yield. A key construction was the installation of (S) absolute configuration in m-hydroxyphenylalanine using asymmetric phase-transfer catalysis in the presence of N-(1-naphthyl) cinchonidinium bromide. Cbz-protected (S)-valine was first coupled to the amino group of (S)-m-triisopropylsilyloxyphenylalanine tert-butyl ester, and the resulting dipeptide after ester cleavage was linked to (3S)-methyl piperazate.
